UPDATE: Equities.com Publishes Video Interview about Immune Pharmaceuticals Financing


Los Angeles, Calif., July 29, 2015 (GLOBE NEWSWIRE) – Equities.com, an interactive online community for financial publication, today published a Video Interview with Dr. Daniel Teper, CEO of Immune Pharmaceuticals, Inc. (NASDAQ:IMNP).Immune Pharmaceuticals secured today funding of up to $21.5 Million from institutional investors, $12 Million in Equity Financing and up to $9.5 Million in Debt Financing. Company to Advance its Immuno-Dermatology and Inflammatory Bowel Disease Product CandidatesLead Compound Bertilimumab, First-in-Class Autoimmune Therapy, a Priority.

(see here: http://immunepharmaceuticals.com/).

Click the following link to watch the video interview on EQUITIES.COM

Please review important disclosures on our website at: EQUITIES.COM

About Immune Pharmaceuticals

Immune Pharmaceuticals Inc. applies a personalized approach to treating and, developing novel, highly-targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company’s lead product candidate, bertilimumab, is in clinical development for moderate to severe ulcerative colitis as well as for bullous pemphigoid, an orphan auto-immune dermatological condition. Immune’s pipeline also includes NanomAbs®, antibody nanoparticle conjugates, for the targeted delivery of chemotherapeutics, and AmiKet™, a topical neuropathic pain drug candidate.

For more information, visit Immune’s website at www.immunepharmaceuticals.com

About Equities.com

Equities.com is an online financial news organization and social community for self-directed investors, public and private companies, market experts, and professional service providers across the global capital markets. The Equities.com Issuer Dashboard is an ideal platform to effectively manage corporate communication and investor awareness campaigns, engage with market intermediaries and financial advisors, and research industry peers. Registered members can leverage our market-leading commentary and content curation, as well as our proprietary research tools. Go tohttp://www.equities.com/community/register to become a member.

info@equities.com

310-822-5500

editor@equities.com

Retrieved from “http://globenewswire.com/news-release/2015/07/29/756177/10143805/en/UPDATE-Equities-com-Publishes-Video-Interview-about-Immune-Pharmaceuticals-Financing.html

About author

This article was written by The Wall Street Analyzer

The Wall Street Analyzer's staff of writers, analysts, publishers, producers, market researchers, and PR professionals aim to provide investors with the tools they need to make informed decisions on buying stock. Our staff is a mix of financial professionals and media savvy individuals whose experiences bring the best talent from both ends of the spectrum. On one hand our financial experience gives us the ability to identify promising, off the grid companies before they are uncovered by the rest of the market, and on the other hand our media experience allows us to produce interviews which appeal to a large audience because we provide a format in which more investors can understand a featured companies' upside. Our philosophy is to turn stock tickers into stories, ideas into headlines, and technical and financial data into easy to understand tidbits, easier to digest and therefore consumed by a larger audience. These interviews provide a jumping off point for investors to do further research into a prospective company. Our editorials seek to provide an out-of-the-box perspective found in few other financial sites.